FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009032810> ?p ?o ?g. }

• W2009032810 endingPage "5358" @default.
• W2009032810 startingPage "5351" @default.
• W2009032810 abstract "BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day 1, whereas bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 for patients on CYP3A enzyme-inducing anti-epileptics [EIAEDs] and 125 mg/m2 for patients not on EIAEDs) were administered on days 1 and 14 of every 28-day cycle. Patients were evaluated after each of the first 2 cycles and then after every other cycle. Treatment continued until progressive disease, unacceptable toxicity, noncompliance, or voluntary withdrawal. The primary end point was progression-free survival at 6 months (PFS-6), and secondary end points included safety and median overall survival (OS). RESULTS: All patients had progression on at least 1 prior bevacizumab regimen and 56% enrolled after either second or third overall progression. The median OS was 5.8 months (95% confidence interval [CI], 4.0-7.0 months) and PFS-6 rate was 16% (95% CI, 5.0%-32.5%). The most common grade 3 or 4 events were hematologic and occurred in 29% of cycles. Nine patients (38%) required dose modification. There were no treatment-related deaths. CONCLUSIONS: Carboplatin, irinotecan, and bevacizumab was associated with modest activity and adequate safety among recurrent GBM patients who progressed on bevacizumab previously. Cancer 2011;. © 2011 American Cancer Society." @default.
• W2009032810 created "2016-06-24" @default.
• W2009032810 creator A5002201007 @default.
• W2009032810 creator A5011590188 @default.
• W2009032810 creator A5014505996 @default.
• W2009032810 creator A5037596103 @default.
• W2009032810 creator A5043001715 @default.
• W2009032810 creator A5050271991 @default.
• W2009032810 creator A5057371623 @default.
• W2009032810 creator A5059965175 @default.
• W2009032810 creator A5071832983 @default.
• W2009032810 creator A5073862375 @default.
• W2009032810 creator A5079356127 @default.
• W2009032810 creator A5083472710 @default.
• W2009032810 date "2011-05-16" @default.
• W2009032810 modified "2023-10-15" @default.
• W2009032810 title "Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy" @default.
• W2009032810 cites W1858161324 @default.
• W2009032810 cites W1898063915 @default.
• W2009032810 cites W1944104521 @default.
• W2009032810 cites W1969328947 @default.
• W2009032810 cites W1977392502 @default.
• W2009032810 cites W1984284981 @default.
• W2009032810 cites W2001355942 @default.
• W2009032810 cites W2002661293 @default.
• W2009032810 cites W2002727873 @default.
• W2009032810 cites W2003200862 @default.
• W2009032810 cites W2006202974 @default.
• W2009032810 cites W2012562754 @default.
• W2009032810 cites W2018016372 @default.
• W2009032810 cites W2027216690 @default.
• W2009032810 cites W2035182290 @default.
• W2009032810 cites W2043585381 @default.
• W2009032810 cites W2046507292 @default.
• W2009032810 cites W2058127641 @default.
• W2009032810 cites W2063622451 @default.
• W2009032810 cites W2093783077 @default.
• W2009032810 cites W2094943043 @default.
• W2009032810 cites W2095822339 @default.
• W2009032810 cites W2099808007 @default.
• W2009032810 cites W2100785570 @default.
• W2009032810 cites W2101711321 @default.
• W2009032810 cites W2108293816 @default.
• W2009032810 cites W2109134893 @default.
• W2009032810 cites W2114159573 @default.
• W2009032810 cites W2114699219 @default.
• W2009032810 cites W2116181319 @default.
• W2009032810 cites W2124863710 @default.
• W2009032810 cites W2127745545 @default.
• W2009032810 cites W2132697290 @default.
• W2009032810 cites W2137832651 @default.
• W2009032810 cites W2145835533 @default.
• W2009032810 cites W2146107023 @default.
• W2009032810 cites W2147143733 @default.
• W2009032810 cites W2157500906 @default.
• W2009032810 cites W2157769714 @default.
• W2009032810 cites W2158106887 @default.
• W2009032810 cites W2158681922 @default.
• W2009032810 cites W2162643152 @default.
• W2009032810 cites W2163458899 @default.
• W2009032810 cites W2164761484 @default.
• W2009032810 cites W2167923186 @default.
• W2009032810 cites W2170367762 @default.
• W2009032810 cites W2325921774 @default.
• W2009032810 cites W4255214479 @default.
• W2009032810 doi "https://doi.org/10.1002/cncr.26188" @default.
• W2009032810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3158844" @default.
• W2009032810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21590689" @default.
• W2009032810 hasPublicationYear "2011" @default.
• W2009032810 type Work @default.
• W2009032810 sameAs 2009032810 @default.
• W2009032810 citedByCount "78" @default.
• W2009032810 countsByYear W20090328102012 @default.
• W2009032810 countsByYear W20090328102013 @default.
• W2009032810 countsByYear W20090328102014 @default.
• W2009032810 countsByYear W20090328102015 @default.
• W2009032810 countsByYear W20090328102016 @default.
• W2009032810 countsByYear W20090328102017 @default.
• W2009032810 countsByYear W20090328102018 @default.
• W2009032810 countsByYear W20090328102019 @default.
• W2009032810 countsByYear W20090328102020 @default.
• W2009032810 countsByYear W20090328102021 @default.
• W2009032810 countsByYear W20090328102022 @default.
• W2009032810 countsByYear W20090328102023 @default.
• W2009032810 crossrefType "journal-article" @default.
• W2009032810 hasAuthorship W2009032810A5002201007 @default.
• W2009032810 hasAuthorship W2009032810A5011590188 @default.
• W2009032810 hasAuthorship W2009032810A5014505996 @default.
• W2009032810 hasAuthorship W2009032810A5037596103 @default.
• W2009032810 hasAuthorship W2009032810A5043001715 @default.
• W2009032810 hasAuthorship W2009032810A5050271991 @default.
• W2009032810 hasAuthorship W2009032810A5057371623 @default.
• W2009032810 hasAuthorship W2009032810A5059965175 @default.
• W2009032810 hasAuthorship W2009032810A5071832983 @default.
• W2009032810 hasAuthorship W2009032810A5073862375 @default.
• W2009032810 hasAuthorship W2009032810A5079356127 @default.
• W2009032810 hasAuthorship W2009032810A5083472710 @default.
• W2009032810 hasBestOaLocation W20090328101 @default.

• next